Three of the transplanted patients were still alive at last follow-up; 1 patient with MECOM-rearranged AML who achieved MRD-positive CRi as best response relapsed 3.8 months post-SCT and 1 patient with TP53-mutated treated secondary AML who achieved MRD-positive CRi as best response relapsed 3.1 months post-SCT, both of whom subsequently died from leukemia-related complications. This evidence concerns the gene MECOM and leukemia.